A <i>post hoc</i> evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Authors PA, TG and MB were employees of GW/Jazz Pharmaceuticals at the time of writing of this article. Author CGC received a research grant from Sanofi and grants for congress participation from Almirall, Biogen, Merck, Novartis, Roche, Sanofi and Teva. Author FP received speaking fees from Bayer, Biogen, Merck, Novartis and Sanofi; served as an advisory board member for Bayer, Biogen, Merck and Novartis; received funding from Pfizer and FISM for epidemiological studies and received grants for congress participation from Bayer, Biogen, Merck, Novartis, Roche, Sanofi and Teva. Author CVS was an employee of the commercial distributor Almirall SA during this analysis and publication process. Author JG has served on advisory boards for and received speaker honoraria from Biogen, Merck, Novartis, Roche, Teva and Sanofi Genzyme."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by GW/Jazz Pharmaceuticals."